CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Dovitinibdrug
Likely dose
Dovitinib 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01262027
NCT01262027Phase 2Completed
CompareCT.gov

A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients With Stage IV HER2-negative Inflammatory Breast Cancer (IBC) and Local or Distant Relapse

M.D. Anderson Cancer Center·interventional·Posted Dec 17, 2010·Updated Jul 30, 2019

In Brief

A Phase 2 clinical trial evaluating Dovitinib for Breast Cancer. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if dovitinib can help to control inflammatory breast cancer. The safety of this drug will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 17, 2010
Enrollment StartJan 27, 2012
Primary CompletionNov 25, 2015
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 15.5 years ago

Interventions

Dovitinibdrug

500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.